Retatrutide and Semaglutide are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Frontier versus benchmark
These two compounds sit at opposite ends of the incretin story. Semaglutide is the molecule that made the whole class famous — a single, highly selective GLP-1 receptor agonist with the deepest clinical evidence base of anything in the field. Retatrutide is the current frontier: a triple agonist that adds two more receptor arms on top of GLP-1 and posted the largest weight-reduction figure yet reported for the class in Phase 2 research. One is an approved, mature medicine studied here as a reagent; the other is investigational and supplied purely for laboratory work. Put them side by side and the comparison is really a question about how far adding receptors can go. For the full three-way context, see our Semaglutide vs Tirzepatide vs Retatrutide comparison.
| Retatrutide | Semaglutide | |
|---|---|---|
| Class | Triple agonist peptide | GLP-1 agonist peptide |
| Receptor targets | GIP + GLP-1 + glucagon (triple) | GLP-1 (single) |
| Structure / MW | 39-aa peptide + C20 fatty-acid tail · ~4,731 Da | 31-aa peptide + C18 fatty-diacid tail · ~4,114 Da |
| Approx. half-life | ~6 days | ~7 days (~165 h) |
| Headline trial result | ~24.2% body-weight reduction (Phase 2 TRIUMPH-1, 48 wk) | ~14.9% body-weight reduction (Phase 3 STEP-1, 68 wk) |
| Main research focus | Obesity, T2D, MASLD · energy expenditure | Obesity, T2D · cardiovascular outcomes |
| Regulatory status | Investigational (Phase 3) | FDA-approved (as a medicine) |
Retatrutide: the triple agonist
Retatrutide (Eli Lilly, code LY3437943) is a first-in-class triple agonist — a single 39-amino-acid peptide that binds and activates the GIP, GLP-1 and glucagon receptors at once. The GLP-1 and GIP arms reduce energy intake through appetite suppression, slowed gastric emptying and glucose-dependent insulin secretion; the third arm, glucagon, is studied as a driver of increased resting energy expenditure. That "energy-in, energy-out" combination is what no single- or dual-agonist compound can reproduce, and it is thought to underpin the magnitude of effect seen in trials. In the Phase 2 TRIUMPH-1 obesity research it posted roughly 24.2% mean body-weight reduction at 48 weeks — the largest figure reported for any incretin-class compound, and notably one that had not plateaued when the trial period ended. A C20 fatty-acid tail promotes reversible albumin binding, giving a ~6-day half-life and a once-weekly research schedule. Retatrutide remains investigational: not approved anywhere, and supplied only as a research reagent. Researchers can buy Retatrutide UK in eight strengths, each ≥99% purity with a COA.
Semaglutide: the single-agonist benchmark
Semaglutide (Novo Nordisk, marketed clinically as Ozempic, Wegovy and Rybelsus) is a pure GLP-1 receptor agonist — one target, engaged with high selectivity. A 31-amino-acid analogue of native GLP-1, it is modified to resist DPP-4 degradation and carries a C18 fatty-diacid chain that extends its half-life to about seven days (~165 hours). In the Phase 3 STEP-1 obesity trial it produced a mean 14.9% body-weight reduction over 68 weeks, and — uniquely in the class — the SELECT trial went on to show a roughly 20% reduction in major adverse cardiovascular events in people with obesity and cardiovascular disease but without diabetes. That depth of hard-endpoint evidence is Semaglutide's real distinction: not breadth of mechanism, but the broadest, most mature dataset of any incretin compound. In a research setting it is the natural reference point, the single-receptor baseline against which multi-agonism is judged. See the Semaglutide knowledgebase profile for the full mechanism and trial detail, or buy Semaglutide UK as research-grade material.
What the differences mean in a research context
The core contrast is mechanism against evidence. Retatrutide changes the number of receptors engaged — three instead of one — and the headline weight-reduction figure rises accordingly, from Semaglutide's ~14.9% to Retatrutide's ~24.2%. That is the multi-agonist thesis in miniature: add complementary receptor systems, raise the ceiling on effect size. The glucagon arm in particular contributes a lever that a selective GLP-1 agonist simply does not have.
But the numbers carry a caveat researchers should hold onto. These figures come from different trials, populations, durations and protocols — STEP-1 ran 68 weeks in a Phase 3 setting, TRIUMPH-1 ran 48 weeks in Phase 2 — so they describe a trend, not a controlled head-to-head ranking. More importantly, the two compounds are at very different stages of maturity. Semaglutide carries an approved, deeply characterised dataset that extends all the way to hard cardiovascular outcomes; Retatrutide's profile is still being written, and as an investigational compound its long-term safety and efficacy picture is not yet settled. Greater effect size in early trials and depth of established evidence are two different currencies.
For research purposes the pair is best understood as the two ends of the agonism ladder held up against each other: the selective benchmark that defined durable metabolic effect through one receptor, and the frontier compound testing how much further three receptors can push it. Both share the same long-acting design logic — a fatty-acid tail, albumin binding, a roughly weekly duration — and both are handled here strictly as lyophilised research reagents.
The bottom line
Semaglutide is the approved single-agonist benchmark with the deepest evidence base in the class; Retatrutide is the investigational triple agonist that currently sits highest on effect size but has a younger dataset. Three receptors versus one, frontier versus benchmark — which matters more depends entirely on the research question. For research-grade material, see our dedicated pages to buy Retatrutide UK and buy Semaglutide UK, each ≥99% purity with a COA. For the wider picture, the three-way incretin comparison slots Tirzepatide in between the two.